Clinical trial
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
NCT05900206
Study timeline
Study start (actual)2023-10-26Date precision: day
Registry last updated2025-09-02
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
Trastuzumab deruxtecanDRUG · verified · RxNorm: trastuzumab deruxtecan
DocetaxelDRUG · verified · RxNorm: docetaxel
PaclitaxelDRUG · verified · RxNorm: paclitaxel
CarboplatinDRUG · verified · RxNorm: carboplatin
TrastuzumabDRUG · verified · RxNorm: trastuzumab
PertuzumabDRUG · verified · RxNorm: pertuzumab
RibociclibDRUG · verified · RxNorm: ribociclib
LetrozoleDRUG · verified · RxNorm: letrozole
EpirubicinDRUG · verified · RxNorm: epirubicin
CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
Sponsors & collaborators
Karolinska University Hospitallead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05900206 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.